Report of Foreign Issuer (6-k)

Date : 10/21/2019 @ 1:26PM
Source : Edgar (US Regulatory)
Stock : Novo Nordisk (NVO)
Quote : 57.04  -0.03 (-0.05%) @ 1:00AM
After Hours
Last Trade
Last $ 57.04 ◊ 0.00 (0.00%)

Report of Foreign Issuer (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

October 21, 2019

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 
 

 

 

 

 

 

Novo Nordisk A/S – Share repurchase programme

 

 

Bagsværd, Denmark, 21 October 2019 – On 9 August 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

 

Under the programme initiated 9 August 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.6 billion in the period from 9 August 2019 to 30 October 2019.

 

Since the announcement as of 14 October 2019, the following transactions have been made:

 

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 5,866,950   2,046,548,389
14 October 2019 130,000 352.55 45,831,545
15 October 2019 125,000 354.59 44,323,378
16 October 2019 125,000 354.12 44,264,428
17 October 2019 120,000 355.37 42,644,714
18 October 2019 118,000 352.56 41,601,723
       
Accumulated under the programme 6,484,950   2,265,214,177

 

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

 

With the transactions stated above, Novo Nordisk owns a total of 37,044,994 B shares of DKK 0.20, corresponding to 1.5% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

 

 

Page 2 of 2

 

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 18 October, Novo Nordisk has since 1 February 2019 repurchased a total of 29,885,962 B shares at an average share price of DKK 331.26 per B share equal to a transaction value of DKK 9,900,167,631.

 

 

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

 

 

Further information

Media:    
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
Kristoffer Due Berg (US) +1 609 235 2989 krdb@novonordisk.com

 

 

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com

CVR no:

24 25 67 90

    Company announcement No 59 / 2019

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: October 21, 2019

 

NOVO NORDISK A/S

 

Lars Fruergaard Jørgensen

Chief Executive Officer

 

 

 

 

 

 

 

 

 

Novo Nordisk (NYSE:NVO)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Novo Nordisk Charts.

Novo Nordisk (NYSE:NVO)
Intraday Stock Chart

Today : Wednesday 20 November 2019

Click Here for more Novo Nordisk Charts.

Latest NVO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.